Health Canada approved 11 of Axxess Pharma Inc.’s new prescription and non-prescription drugs as management anticipates annual sales from the recently approved drugs to exceed $6 million.
All of the drugs are now being sold in Canada and have been submitted to Latin America for approval and distribution throughout the region.
"This is an exciting time for our company. We continue to introduce effective, new, high demand prescription and non-prescription drugs into the market. Our 11 Health Canada approved drugs are anticipated to generate over $6 million in annual sales. All of these products are sold under the Axxess Pharma brand name," said Gerald Sequeira, President and CEO.
"We look forward to receiving approval on 11 additional drugs within the next 3 months."
The current list of drugs that have been approved by Health Canada include:
• Triferrex 150 which is a non-constipating iron supplement for men and women
• Triferrex Pre-Natal (PN) which is a non-constipating multi-vitamin to be used prior to, during and after pregnancy (post partum)
• Gravagol, used for the treatment of migraine headaches
• Monurol, used as a onetime treatment for urinary tract infections in women
• Urasol, a non-antibiotic for long-term treatment of urinary tract infections
• Somonol, used as a hypnotic
• Soropon, used exclusively in the treatment of cradle cap in infants
• Vivol, used as tranquilizer to relieve stress and tension
• Kemsol, used to help treat scleroderma which is a skin disease
• Hydraxx 1 percent (fragrance), used by dermatologists for very dry skin
• Hydraxx 2 percent (non-fragrance), used by dermatologists for very dry skin
Axxess Pharma Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally.
Source: Axxess Pharma Inc.
All of the drugs are now being sold in Canada and have been submitted to Latin America for approval and distribution throughout the region.
"This is an exciting time for our company. We continue to introduce effective, new, high demand prescription and non-prescription drugs into the market. Our 11 Health Canada approved drugs are anticipated to generate over $6 million in annual sales. All of these products are sold under the Axxess Pharma brand name," said Gerald Sequeira, President and CEO.
"We look forward to receiving approval on 11 additional drugs within the next 3 months."
The current list of drugs that have been approved by Health Canada include:
• Triferrex 150 which is a non-constipating iron supplement for men and women
• Triferrex Pre-Natal (PN) which is a non-constipating multi-vitamin to be used prior to, during and after pregnancy (post partum)
• Gravagol, used for the treatment of migraine headaches
• Monurol, used as a onetime treatment for urinary tract infections in women
• Urasol, a non-antibiotic for long-term treatment of urinary tract infections
• Somonol, used as a hypnotic
• Soropon, used exclusively in the treatment of cradle cap in infants
• Vivol, used as tranquilizer to relieve stress and tension
• Kemsol, used to help treat scleroderma which is a skin disease
• Hydraxx 1 percent (fragrance), used by dermatologists for very dry skin
• Hydraxx 2 percent (non-fragrance), used by dermatologists for very dry skin
Axxess Pharma Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally.
Source: Axxess Pharma Inc.
